Page last updated: 2024-10-15

aurodox

Description

Aurodox: Antibiotic obtained from a Streptomyces variant considered as possibly effective against Streptococcus pyogenes infections. It may promote growth in poultry. [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID135509117
CHEMBL ID3221419
SCHEMBL ID687429
MeSH IDM0001343

Synonyms (27)

Synonym
antibiotic x-5108
nsc-233989
nsc 233989
x 5108
mocimycin, 1-methyl-
1-methylmocimycin
n-methyl kirromycin
goldinomycin
aurodox
MAU ,
goldinodox
DB04124
unii-pgp5rzh64g
x-5108
pgp5rzh64g ,
12704-90-4
aurodox [mi]
CHEMBL3221419
SCHEMBL687429
(2s)-n-[(2e,4e,6s,7r)-7-[(2s,3s,4r,5r)-3,4-dihydroxy-5-[(1e,3e,5e)-7-(4-hydroxy-1-methyl-2-oxopyridin-3-yl)-6-methyl-7-oxohepta-1,3,5-trienyl]oxolan-2-yl]-6-methoxy-5-methylocta-2,4-dienyl]-2-[(2r,3r,4r,6s)-2,3,4-trihydroxy-5,5-dimethyl-6-[(1e,3z)-penta-1
aurodox; 1-methylmocimycin; antibiotic x-5108; goldinodox; goldinomycin
(2s)-n-[(2e,4e,6s,7r)-7-{(2s,3s,4r,5r)-3,4-dihydroxy-5-[(1e,3e,5e)-7-(4-hydroxy-1-methyl-2-oxo-1,2-dihydropyridin-3-yl)-6-methyl-7-oxohepta-1,3,5-trien-1-yl]tetrahydrofuran-2-yl}-6-methoxy-5-methylocta-2,4-dien-1-yl]-2-{(2r,3r,4r,6s)-2,3,4-trihydroxy-5,5-
Q27094966
DTXSID801043992
AKOS040750636
HY-118992
CS-0078314

Research Excerpts

Overview

Aurodox is a linear polyketide natural product that is produced by Streptomyces goldiniensis. Little is known about the biosynthetic gene cluster (BGC) that encodes its production. Aurod Rox is a member of the family of kirromycin antibiotics.

ExcerptReference
"Aurodox is a linear polyketide natural product that is produced by Streptomyces goldiniensis, yet little is known about aurodox biosynthesis or the nature of the biosynthetic gene cluster (BGC) that encodes its production."( Biosynthesis of Aurodox, a Type III Secretion System Inhibitor from Streptomyces goldiniensis.
Braes, RE; Burley, GA; Giard, J; Hoskisson, PA; McHugh, RE; McKean, IJW; Munnoch, JT; Peschke, F; Roe, AJ; Taladriz-Sender, A, 2022
)
"Aurodox is a member of the family of kirromycin antibiotics, which inhibit protein biosynthesis by binding to elongation factor Tu (EF-Tu). "( Conformational change of elongation factor Tu (EF-Tu) induced by antibiotic binding. Crystal structure of the complex between EF-Tu.GDP and aurodox.
Hilgenfeld, R; Mesters, JR; Palm, GJ; Vogeley, L, 2001
)
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Bioassays (4)

Assay IDTitleYearJournalArticle
AID1120962Inhibition of Escherichia coli T3SS-mediated hemolysis of erythrocytes2013MedChemComm, Jan-01, Volume: 4, Issue:1
Small molecules aimed at type III secretion systems to inhibit bacterial virulence.
AID1873322Antibacterial activity against enteropathogenic Escherichia coli2022Bioorganic & medicinal chemistry letters, 08-01, Volume: 69Insights into the structure-activity relationship of a type III secretion system inhibitor, aurodox.
AID1873321Inhibition of bacterial type III secretion system in enteropathogenic Escherichia coli2022Bioorganic & medicinal chemistry letters, 08-01, Volume: 69Insights into the structure-activity relationship of a type III secretion system inhibitor, aurodox.
AID1873323Selectivity index, ratio of IC50 for antibacterial activity against enteropathogenic Escherichia coli to IC50 for inhibition of bacterial type III secretion system in enteropathogenic Escherichia coli2022Bioorganic & medicinal chemistry letters, 08-01, Volume: 69Insights into the structure-activity relationship of a type III secretion system inhibitor, aurodox.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (30)

TimeframeStudies, This Drug (%)All Drugs %
pre-199014 (46.67)18.7374
1990's9 (30.00)18.2507
2000's1 (3.33)29.6817
2010's4 (13.33)24.3611
2020's2 (6.67)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews0 (0.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other30 (100.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]